The present invention provides novel compounds suitable for use as proteasome inhibitors. The present invention also provides pharmaceutical compositions comprising the present compounds and methods of using such compositions for treating various diseases.
This is the Chinese granted invention patent CN 101772507 B (application no. 200780100142.3, filed 2007.08.06, granted 2012.12.12), filed by Millennium Pharmaceuticals of Massachusetts, USA, with inventors Edward J. Olhava and Mihaela D. Danca. It is a PCT national-phase entry (PCT/US2007/017440, published as WO 2009/020448) and runs 3 pages of claims plus 19 pages of description.
The patent concerns boronic acid and boronic ester compounds described as useful proteasome inhibitors, pharmaceutical compositions containing them, and methods of using those compositions to treat diseases. The claims define formula (I) compounds or their pharmaceutically acceptable salts or boronic anhydrides, list numerous named [(1R)-1-({[(benzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acids and their mannitol esters, and include a composition claim and a use claim for preparing a medicament for treating cancer. The background section reviews earlier peptide boronic acid and proteasome inhibitor literature. This manual is written in Chinese.
It covers boronic acid and boronic ester compounds described as useful proteasome inhibitors, including many specifically named [(1R)-1-({[(benzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acids, their pharmaceutically acceptable salts and boronic anhydrides.
The claims state a use of the compounds for preparing a medicament for treating cancer.
Yes, a claim covers a pharmaceutical composition containing a compound of any of claims 1-11 together with a pharmaceutically acceptable carrier.
The patentee is Millennium Pharmaceuticals (米伦纽姆医药公司), located in Massachusetts, USA.